Double Therapy Promising Treatment Of Tuberculosis With C. Difficile, Finds Study
- byDoctor News Daily Team
- 02 July, 2025
- 0 Comments
- 0 Mins
 
                            
                                    Patients with tuberculosis and suffering from C. difficile infections (CDI) concurrently,are a major challenge to physicians.
Clostridiun difficile infecton (CDI) is a major hospital problem, associated with long time antibiotic treatment. Clostridium difficile colitis results from a disturbance of the normal bacterial flora of the colon and the release of toxins that cause mucosal inflammation and damage.
The aim of the present study was to underlie the percent of TB patients affected by CDI, the impact of CDI in tuberculosis (TB) evolution, length of hospitalization and the effect of treatment on CDI recurrences.
To do the same, a team, led by Mara Popescu-Hagen,undertook a observational, retrospective study in the Institute of Pneumology "Marius Nasta" from March 2018 to May 2019, on 29 patients (17 men, 12 wemen) with tuberculosis and Clostridium difficile infection.
CDI was diagnosed by an immunoenzymatic assay (C. difficile TOX A/B II) for patients who developed diarrhea. The clinical data collected in this study were age, clinical characteristics, length of hospitalization, CDI treatment, comorbidities, medication history, and the use of antibiotics, especially anti-tuberculosis medication.
All TB patients (mean age 57.1 years) confirmed with CDI were included in the study. Stool characteristics, frequency of defecation, abdominal pain, treatment and relapses of CDI were monitored.
On data analysis, the following facts emerged.
Most patients in the study group had a diarrheal episode within 3 weeks of initiating DOTS treatment.
Abdominal pain and cramps were present in all 29 patients, 41.38% of patients experienced the altered general condition.
None of these cases have received treatment with proton pump inhibitors in the last 3 months prior to the onset of disease.17 patients already had a previous hospital admission before the first diarrheal episode.
Of these 17 patients, 14 had relapses of C. difficile infection,
The age group over 70 is predominantly affected. Analyzing the relationship between the regimen used and the number of recurrences related to each category in the group of 29 patients, it emerged that there were 7 patients in whom Metronidazole was used as the only antibiotic.
Of these, 6 had relapses of C. difficile infection. Treatment with Vancomycin was given to 7 patients, of whom 6 relapses.
The fewest relapses, 4 out of 13 cases, were in those treated with double therapy, Metronidazole in combination with Vancomycin.
Taking a cue from the results, the researcherd concluded that," The fewest relapses were in patients treated with double therapy, with 30.77% of all those who benefited from this regimen. The length of hospitalization of cases with TB and CDI has been 56 days. The judicious prescription of antibiotic treatments with large specter and studies about initial double therapy of CDI in TB patients must be continued."
For full story follow the link: https://doi.org/10.1016/j.chest.2020.09.044
Primary source: CHEST 2020 Annual Meeting.
                                
    Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
    The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
    Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
    If you come across any inconsistencies, please reach out to us at 
    admin@doctornewsdaily.com.
    We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
    By using this website, you agree to our 
    Terms of Use, 
    Privacy Policy, and 
    Advertisement Policy.
    For further details, please review our 
    Full Disclaimer.
Recent News
Merck Keytruda wins European Commission nod for lo...
- 30 October, 2025
UP NEET 2025 round 3 allotment results postponed
- 30 October, 2025
Achin Gupta to succeed Umang Vohra as Cipla MD, GC...
- 30 October, 2025
Daily Newsletter
Get all the top stories from Blogs to keep track.
 
                     
                    
0 Comments
Post a comment
No comments yet. Be the first to comment!